Axios writes of a JAMA Network Open report that found nearly $50 billion or a third of Medicare Part D costs in 2016 were for drugs with absent cost-effectiveness analyses. The lack of a quality analysis that weighs the relative cost with outcomes of these drugs may create hurdles toward efforts aimed at addressing drug spending in terms of value.
- Axios: Pricey drugs paid by Medicare lack cost-effectiveness data
- Availability of Cost-effectiveness Studies for Drugs With High Medicare Part D Expenditures. JAMA Network Open. June 18, 2021